Agenda

Date and TimeTitle
Oct 13, 2021 (Eastern)
12:00pm - 1:00pm
Exact Sciences: The Evolution of Genomics inBreast

Program Description: Dr. Christy Russell (Sr. Director, Global Medical Affairs at Exact Sciences) will discuss the development and utility of the Oncotype DX Breast Recurrence Score® test in early-stage, HR-positive, HER2-negative breast cancer and future innovations in the early and advanced breast cancer space. 

This is a Non-CME/CE presentation.

Sponsored by Exact Sciences

Oct 13, 2021 (Eastern)
6:00pm - 8:35pm
Session I: News and Views: HR+ Breast Cancer

6:00 PM ET | Welcome and Introduction                                          Presenter: Massimo Cristofanilli, MD, FACP; Erika Hamilton, MD 

6:03 PM ET | Selecting and Sequencing Treatment: HR-Positive Metastatic Breast Cancer  
Presenter: Hope Rugo, MD 

6:27 PM ET |  Precision Medicine in HR-Positive Metastatic Breast Cancer  
Presenter: Sarat Chandarlapaty, MD 

6:49 PM ET |  Selecting and Sequencing Treatment: HR-Positive Early Breast Cancer  
Presenter: Kevin Kalinsky, MD 
 
7:07 PM ET | Pulse Check: Novel Hormonal Innovations in Breast Cancer  
Presenter: Komal Jhaveri, MD 
 
7:24 PM ET | Novel Therapeutics Beyond Endocrine Therapy  
Presenter: Aditya Bardia, MD 

7:40 PM ET | Putting the Patient First: HR-Positive Breast Cancer 
Presenter: Kelly Shanahan, MD 
 
7:55 PM ET | Live Q&A 

8:30 PM ET | Day 1 Closing Remarks 

Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP
Supported by an independent educational grant from Daiichi Sankyo, Inc.
Supported by an independent educational grant from Eisai, Inc.
Supported by an independent educational grant from Gilead Sciences, Inc.

ACCREDITATION INFORMATION

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 2.5 contact hour(s) of nursing continuing professional development for RNs and APNs; 2.0 Nursing pharmacology content hours.

Oct 14, 2021 (Eastern)
6:00pm - 8:40pm
Session II: The HER2 View on Breast Cancer

6:00 PM ET | Introduction 
Moderators: Sara Tolaney, MD, MPH; Shanu Modi, MD 

6:03 PM ET | Assessing HER2 Breast Cancer 
Presenter: Antonio Wolff, MD 

6:19 PM ET | Approaches for Stage I HER2-Positive Disease  
Presenter: Sara Tolaney, MD, MPH 

6:35 PM ET | Approaches to Treatment of Early HER2-Positive Breast Cancer    
Presenter: Mark Pegram, MD 

6:50 PM ET | Novel Approaches to Escalate and De-Escalate Therapy for Early Stage HER2-Positive Disease 
Presenter: Sara Hurvitz, MD 

7:07 PM ET | Selecting and Sequencing Treatment: New Metastatic Treatments in Context
Presenter: Shanu Modi, MD
 
7:22  PM ET | Treatment Approaches for HER2-Positive Brain Metastases
Presenter: Carey Anders, MD    

7:33 PM ET | Novel and Emerging Approaches for HER2-Positive Disease 
Presenter: Ian Krop, MD 

7:49 PM ET | Putting the Patient First: Toxicity Management   
Presenter: Reshma Mahtani, MD 

8:08 PM ET | Live Q&A 

8:38 PM ET | Closing Remarks 

Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP
Supported by an independent educational grant from Daiichi Sankyo, Inc.
Supported by an independent educational grant from Eisai, Inc.
Supported by an independent educational grant from Gilead Sciences, Inc.

ACCREDITATION INFORMATION

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this live event for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 2.5 contact hour(s) of nursing continuing professional development for RNs and APNs; 2.0 Nursing pharmacology content hours.

Oct 15, 2021 (Eastern)
2:30pm - 5:05pm
Session III: Turning Negative into Positives in Triple Negative Breast Cancer

2:30 PM ET | Introduction 
Moderators: Joyce O'Shaughnessy, MD; Rashmi Murthy, MD, MBE 

2:33 PM ET |Current Understanding of Triple Negative Breast Cancer Subtypes 
Presenter: Brian Lehmann, PhD 

2:46 PM ET | Emerging Immunotherapy in the Metastatic Setting  Presenter: Jennifer Litton, MD 

3:06 PM ET | Immunotherapy in the Curative Setting.                     Presenter: Joyce O’Shaughnessy, MD 

3:31 PM ET | PARP Inhibitors in the Early and Metastatic Setting  
Presenter: Reva Basho, MD 

3:56 PM ET | Pulse Check: Innovations in Metastatic TNBC 
Presenter: Tiffany Traina, MD

4:20 PM ET | The Role of Homologous Recombination Deficiency Biomarkers in TNBC 
Presenter: Priyanka Sharma, MD 

4:40 PM ET | Live Q&A 

4:58 PM ET | Closing Remarks 

Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP
Supported by an independent educational grant from Daiichi Sankyo, Inc.
Supported by an independent educational grant from Eisai, Inc.
Supported by an independent educational grant from Gilead Sciences, Inc.

ACCREDITATION INFORMATION

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this live event for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 2.5 contact hour(s) of nursing continuing professional development for RNs and APNs; 2.0 nursing pharmacology content hours.

Oct 16, 2021 (Eastern)
10:30am - 12:32pm
Session IV: Case Challenges

10:30 AM ET | Welcome and Introductions    
Presenter: Edith Perez, MD 

10:33 AM ET | HR-Positive Breast Case Challenges/COVID Patient Management 
Presenter: Jane Meisel, MD 

10:56 AM ET | HER2-Positive Breast Case Challenges/COVID Patient Management
Presenter: James Abraham, MD 

11:23 PM ET | Triple Negative Breast Cancer Case Challenges/COVID Patient Management 
Presenter: Rita Nanda, MD   

11:42 PM ET | Live Q&A 

12:40 PM ET | Closing Remarks 

Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP
Supported by an independent educational grant from Daiichi Sankyo, Inc.
Supported by an independent educational grant from Eisai, Inc.
Supported by an independent educational grant from Gilead Sciences, Inc.

ACCREDITATION INFORMATION

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians
Medscape, LLC designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 1.75 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 nursing pharmacology content hours.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based 1.75 contact hours and 0.25 CEUs. Universal Activity number JA0007105-0000-21-530-L01-P.